GW Pharmaceuticals says Epidiolex would price $32,500 each year
GW Pharmaceuticals has revealed the price of Epidiolex, the initial cannabis-based medicine which has been authorized because of the United States Food and Drug management. Based on the medication manufacturer, Epidiolex would price each client on average $32,000 each year.
British-based GW Pharmaceuticals made the revelation on a call with investors week that is last.
Treatment for uncommon type of epilepsy
Epidiolex happens to be created as treatment plan for two uncommon kinds of youth epilepsy: Dravet syndrome and Lennox-Gastaut problem. Both of these medical conditions are seen as an regular and seizures that are hard-to-treat. Continue reading «GW Pharmaceuticals says Epidiolex would price $32,500 each year»